Pharmacogenomic Guidance Could Foretell Upcoming Diagnostics Draft
FDA will not use genomic information voluntarily submitted by industry for regulatory decisions on drug or biologics applications, according to a guidance issued March 22
FDA will not use genomic information voluntarily submitted by industry for regulatory decisions on drug or biologics applications, according to a guidance issued March 22